Lenvatinib (LEN) plus pembrolizumab (PEMBRO) treatment in patients (pts) with metastatic clear cell renal cell carcinoma (RCC): Final results of a phase 1b/2 trial.

被引：0

作者：

Lee, Chung-Han

Shah, Amishi Yogesh

Hsieh, James J.

Rao, Arpit

Pinto, Alvaro

Bilen, Mehmet Asim

Cohn, Allen Lee

DiSimone, Christopher

Shaffer, David R.

Sarrio, Regina Girones

Ribe, Sara Gunnestad

Wu, Jane

Schmidt, Emmett V.

Kubiak, Peter

Okpara, Chinyere

Smith, Alan D.

Motzer, Robert J.

机构：

[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA

[3] Washington Univ, Sch Med, Dept Med, Oncol Div, St Louis, MO 63110 USA

[4] South Texas Accelerated Res Therapeut, Dept Clin Res, San Antonio, TX USA

[5] Hosp Univ La Paz, Serv Oncol, Madrid, Spain

[6] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA

[7] US Oncol Res, Rocky Mt Canc Ctr, Med Oncol, Denver, CO USA

[8] Arizona Oncol Associates, Med Oncol Hematol, Tucson, AZ USA

[9] New York Oncol Hematol, US Oncol Res, Med Oncol, Albany, NY USA

[10] Hosp Univ & Politecn FE, Med Oncol Serv, Valencia, Spain

[11] Sorlandet Hosp Kristiansand, Med Oncol, Kristiansand, Norway

[12] Eisai Inc, Biostat, Woodcliff Lake, NJ USA

[13] Merck & Co Inc, Clin Res, Kenilworth, NJ USA

[14] Eisai Inc, Clin Res, Woodcliff Lake, NJ USA

[15] Eisai Ltd, Clin Res, Hatfield, Herts, England

[16] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.e16542

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e16542

引用

页数：3

共 50 条

[1] A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with renal cell carcinoma
Lee, C-H.
Makker, V.
Rasco, D.
Taylor, M.
Dutcus, C.
Shumaker, R.
Schmidt, E. V.
Stepan, D.
Li, D.
Motzer, R. J.
ANNALS OF ONCOLOGY, 2017, 28
[2] Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a firstline treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study).
Motzer, Robert J.
Porta, Camillo
Eto, Masatoshi
Powles, Thomas
Grunwald, Viktor
Hutson, Thomas E.
Alekseev, Boris
Rha, Sun Young
Kopyltsov, Evgeny
Mendez Vidal, Maria Jose
Hong, Sung-Hoo
Kapoor, Anil
Gordoa, Teresa Alonso
Goh, Jeffrey C.
Merchan, Jaime R.
Smith, Alan D.
Mody, Kalgi
Perini, Rodolfo F.
Xing Dongyuan
Choueiri, Toni K.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
[3] A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results
Llovet, Josep
Finn, Richard
Ikeda, Masfumi
Sung, Max
Baron, Ari
Kudo, Masatoshi
Okusaka, Takuji
Kobayashi, Masahiro
Kumada, Hiromitsu
Kaneko, Suichi
Pracht, Marc
Mamontov, Konstantin
Meyer, Tim
Mody, Kalgi
Kubota, Tomoki
Dutcus, Corina
Saito, Kenichi
Siegel, Abby
Dubrovsky, Leonid
Young, Louise
Zhu, Andrew X.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 189 - 190
[4] Correlative serum biomarker analyses: Lenvatinib (LEN) plus pembrolizumab (PEMBRO) in a phase Ib/II trial in advanced renal cell carcinoma (RCC)
Lee, C-H.
Adachi, Y.
Ikezawa, H.
Li, S. D.
Funahashi, Y.
Minoshima, Y.
Kubiak, P.
Perini, R.
Ren, M.
Smith, A. D.
Motzer, R. J.
ANNALS OF ONCOLOGY, 2020, 31 : S564 - S565
[5] A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC).
Ikeda, Masafumi
Sung, Max W.
Kudo, Masatoshi
Kobayashi, Masahiro
Baron, Ari David
Finn, Richard S.
Kaneko, Shuichi
Zhu, Andrew X.
Kubota, Tomoki
Kraljevic, Silvija
Ishikawa, Kohei
Siegel, Abby B.
Kumada, Hiromitsu
Okusaka, Takuji
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[6] A phase Ib/II trial of lenvatinib (LEN) plus pembrolizumab (Pembro) in patients (Pts) with endometrial carcinoma.
Makker, Vicky
Rasco, Drew W.
Dutcus, Corina E.
Stepan, Daniel E.
Li, Di
Schmidt, Emmett V.
Shumaker, Robert Charles
Taylor, Matthew H.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[7] Updated efficacy of lenvatinib (LEN) plus pembrolizumab (PEMBRO) vs sunitinib (SUN) in patients (pts) with advanced renal cell carcinoma (aRCC) in the CLEAR study
Porta, C. G.
Eto, M.
Motzer, R. J.
De Giorgi, U. F. F.
Buchler, T.
Basappa, N. S.
Mendez Vidal, M. J.
Tjulandin, S.
Park, S. H.
Melichar, B.
Hutson, T. E.
Alemany, C.
McGregor, B.
He, C. S.
Perini, R.
Mody, K.
McKenzie, J.
Choueiri, T. K.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1205 - +
[8] Analysis of the CLEAR study in patients (pts) with advanced renal cell carcinoma (RCC): Depth of response and efficacy for selected subgroups in the lenvatinib (LEN) plus pembrolizumab (PEMBRO) and sunitinib (SUN) treatment arms.
Grunwald, Viktor
Powles, Thomas
Kopyltsov, Evgeny
Kozlov, Vadim
Gordoa, Teresa Alonso
Eto, Masatoshi
Hutson, Thomas E.
Motzer, Robert J.
Winquist, Eric
Maroto-Rey, Pablo
Keam, Bhumsuk
Procopio, Giuseppe
Wong, Shirley
Melichar, Bohuslav
Rolland, Frederic
Oya, Mototsugu
Rodriguez-Lopez, Karla
Saito, Kenichi
Smith, Alan D.
Porta, Camillo
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[9] Pegilodecakin with nivolumab (nivo) or pembrolizumab (pembro) in patients (pts) with metastatic renal cell carcinoma (RCC).
Tannir, Nizar M.
Naing, Aung
Infante, Jeffrey R.
Papadopoulos, Kyriakos P.
Wong, Deborah J. L.
Korn, Michael
Aljumaily, Raid
Autio, Karen A.
Pant, Shubham
Bauer, Todd Michael
Drakaki, Alexandra
Daver, Naval Guastad
Hung, Annie
Van Vlasselaer, Peter
Leveque, Joseph
Oft, Martin
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[10] Efficacy and safety of lenvatinib (LEN) plus pembrolizumab (PEMBRO) versus sunitinib (SUN) in the East Asian subset of patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial.
Rha, Sun Young
Choueiri, Toni K.
Matveev, Vsevolod B.
Alyasova, Anna
Hong, Sung-Hoo
Gordoa, Teresa Alonso
Gurney, Howard
Bjarnason, Georg A.
Buchler, Tomas
Pedrazzoli, Paolo
Takagi, Toshio
Park, Se Hoon
Lee, Jae-Lyun
Perini, Rodolfo F.
He, Cixin
McKenzie, Jodi A.
Eto, Masatoshi
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)

← 1 2 3 4 5 →